ストックスクリーナーアプリを入手
6.98
4.49%
0.30
前日終値:
$6.68
開ける：
$6.79
24時間の取引高:
546.63K
Relative Volume:
0.78
時価総額：
$333.42M
収益：
-
当期純損益:
$-59.85M
株価収益率:
-7.8808
EPS:
-0.8857
ネットキャッシュフロー:
$-54.54M
1週間 パフォーマンス:
-1.97%
1か月 パフォーマンス:
-1.55%
6か月 パフォーマンス:
+232.38%
1年 パフォーマンス:
+436.92%
1日の値動き範囲:
$6.61
$7.00
1週間の範囲:
$5.87
$7.22
52週間の値動き範囲:
$1.05
$8.04
Climb Bio Inc Stock (CLYM) Company Profile
Compare CLYM vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
6.98 | 333.42M | 0 | -59.85M | -54.54M | -0.8857 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | 開始されました | Truist | Buy |
| 2026-03-11 | 開始されました | Raymond James | Strong Buy |
| 2026-03-05 | 開始されました | Wedbush | Outperform |
| 2026-02-13 | 開始されました | Piper Sandler | Overweight |
| 2025-10-16 | 開始されました | William Blair | Outperform |
| 2025-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2025-08-15 | 開始されました | Robert W. Baird | Outperform |
| 2025-06-06 | 開始されました | Oppenheimer | Outperform |
| 2025-05-22 | 開始されました | BTIG Research | Buy |
| 2024-12-02 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Climb Bio Inc (CLYM) 最新ニュース
B Riley Securities initiates coverage of Climb Bio (CLYM) with buy recommendation - MSN
B. Riley Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $26 - Moomoo
B. Riley Financial Initiates Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential - Investing.com
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential By Investing.com - Investing.com Australia
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
If You Invested $1,000 in Climb Bio (CLYM) - Stock Titan
Aug Breakouts: Is Climb Bio Inc forming a double bottom2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? - MSN
Climb Bio (CLYM) Receives 'Buy' Rating from Truist Securities | - GuruFocus
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Truist initiates Climb Bio stock with buy rating on drug potential - Investing.com Australia
Truist initiates Climb Bio stock with buy rating on drug potential By Investing.com - Investing.com South Africa
Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 - MarketBeat
HC Wainwright Has Pessimistic View of Climb Bio Q1 Earnings - Defense World
Pharma News: Will Climb Bio Inc benefit from green energy policiesMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Targets Report: Can Climb Bio Inc sustain its profitability2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Raymond James initiates coverage of Climb Bio (CLYM) with strong buy recommendation - MSN
What is HC Wainwright's Forecast for Climb Bio Q1 Earnings? - MarketBeat
Analysts’ Weekly Ratings Updates for Climb Bio (CLYM) - Defense World
Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026 - Meyka
Research Analysts Issue Forecasts for Climb Bio Q1 Earnings - Defense World
Climb Bio (NASDAQ:CLYM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for Climb Bio Issued By HC Wainwright - MarketBeat
Raymond James initiates Climb Bio stock coverage with strong buy on renal pipeline - Investing.com UK
Raymond James initiates Climb Bio stock coverage with strong buy on renal pipeline By Investing.com - Investing.com South Africa
Climb Bio (NASDAQ:CLYM) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Climb Bio (NASDAQ:CLYM) Price Target Raised to $15.00 - MarketBeat
Climb Bio price target raised to $11 from $9 at HC Wainwright - MSN
Climb Bio (NASDAQ:CLYM) Research Coverage Started at Wedbush - Defense World
Published on: 2026-03-08 04:23:03 - baoquankhu1.vn
HC Wainwright forecasts 2026 data readouts for Climb Bio’s (CLYM) Budoprutug across clinical tracks - MSN
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP) and Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
Fed Meeting: Is Climb Bio Inc a stock for growth or value investors2025 Biggest Moves & Consistent Income Trade Ideas - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Wedbush Raises Price Target for CLYM, Maintains 'Outperform' Rat - GuruFocus
Baird Maintains "Outperform" Rating, Raises Price Target for CLY - GuruFocus
Climb Bio Inc (CLYM) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):